Sauson Soldozy

Dr. Sauson Soldozy

Department of Neurosurgery, University of Miami, Miami, FL, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
SSSauson Soldozy
Sauson Soldozy
DEDaniel G. Eichberg
Daniel G. Eichberg
AMAlexis A. Morell
Alexis A. Morell
ELEvan Luther
Evan Luther
VLVictor M Lu
Victor M Lu
Michael E. IvanMichael E. Ivan
Michael E. Ivan
Brain tumor incidence is on the rise, and glioblastoma comprises the majority of primary tumors. Despite maximal safe resection and adjuvant chemoradiation, median survival for high-grade glioma remains poor. For this reason, it is important to develop and incorporate new treatment strategies. Oncolytic virotherapy has emerged as a viable new therapeutic entity to fill this gap. Preclinical research has shown oncolytic virotherapy to be a robust and effective treatment option for brain tumors, and clinical trials for both adult and pediatric high-grade glioma are underway. The unique and protected environment of the nervous system, in part due to the blood–brain barrier, prevents traditional systemic therapies from achieving adequate penetration. Brain tumors are also heterogenous in nature due to their diverse molecular profiles, further complicating systemic treatment efforts. Oncolytic viruses may serve to fill this gap in brain tumor treatment given their amenability to genetic modification and ability to target unique tumor epitopes. In addition, direct inoculation of the oncolytic virus agent to the tumor bed following surgical resection absolves risk of systemic side effects and ensures adequate delivery. As virotherapy transitions from bench to bedside, it is important to discuss factors to make this transition more seamless. In this article, we describe the current clinical evidence as it pertains to oncolytic virotherapy and the treatment of brain tumors as well as factors to consider for its incorporation into neurosurgical workflow.

1 June 2022 in World Neurosurgery
Verified
Journal Article
Closed access
AJAria M. Jamshidi
Aria M. Jamshidi
SSSauson Soldozy
Sauson Soldozy
TETurki Elarjani
Turki Elarjani
JBJoshua D. Burks
Joshua D. Burks
ELEvan Luther
Evan Luther
RSRobert M. Starke
Robert M. Starke